Net Profit Margin
since 2005
Calculation
Eli Lilly & Co., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss)1 | ÷ | Revenue1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 23.51% | = | 100 | × | 10,590,000) | ÷ | 45,042,700) |
| Dec 31, 2023 | 15.36% | = | 100 | × | 5,240,400) | ÷ | 34,124,100) |
| Dec 31, 2022 | 21.88% | = | 100 | × | 6,244,800) | ÷ | 28,541,400) |
| Dec 31, 2021 | 19.71% | = | 100 | × | 5,581,700) | ÷ | 28,318,400) |
| Dec 31, 2020 | 25.24% | = | 100 | × | 6,193,700) | ÷ | 24,539,800) |
| Dec 31, 2019 | 37.27% | = | 100 | × | 8,318,400) | ÷ | 22,319,500) |
| Dec 31, 2018 | 13.16% | = | 100 | × | 3,232,000) | ÷ | 24,555,700) |
| Dec 31, 2017 | -0.89% | = | 100 | × | (204,100) | ÷ | 22,871,300) |
| Dec 31, 2016 | 12.90% | = | 100 | × | 2,737,600) | ÷ | 21,222,100) |
| Dec 31, 2015 | 12.07% | = | 100 | × | 2,408,400) | ÷ | 19,958,700) |
| Dec 31, 2014 | 12.19% | = | 100 | × | 2,390,500) | ÷ | 19,615,600) |
| Dec 31, 2013 | 20.27% | = | 100 | × | 4,684,800) | ÷ | 23,113,100) |
| Dec 31, 2012 | 18.09% | = | 100 | × | 4,088,600) | ÷ | 22,603,400) |
| Dec 31, 2011 | 17.90% | = | 100 | × | 4,347,700) | ÷ | 24,286,500) |
| Dec 31, 2010 | 21.97% | = | 100 | × | 5,069,500) | ÷ | 23,076,000) |
| Dec 31, 2009 | 19.82% | = | 100 | × | 4,328,800) | ÷ | 21,836,000) |
| Dec 31, 2008 | -10.17% | = | 100 | × | (2,071,900) | ÷ | 20,378,000) |
| Dec 31, 2007 | 15.85% | = | 100 | × | 2,953,000) | ÷ | 18,633,500) |
| Dec 31, 2006 | 16.97% | = | 100 | × | 2,662,700) | ÷ | 15,691,000) |
| Dec 31, 2005 | 13.52% | = | 100 | × | 1,979,600) | ÷ | 14,645,300) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The net income figures exhibit substantial volatility over the given time period. Starting from approximately 1.98 billion USD in 2005, net income generally increased reaching a peak of over 8.3 billion USD in 2019. However, there were notable fluctuations, including a significant net loss in 2008 at approximately negative 2.07 billion USD and a negative figure in 2017 as well. Following 2019, net income decreased but remained positive, with values oscillating until reaching a notable increase again in 2024, peaking at 10.59 billion USD.
Revenue demonstrates a clear upward trend throughout the period under review. Beginning at approximately 14.65 billion USD in 2005, revenue steadily increased with a few periods of decline or slower growth, such as in 2008 and a drop in 2014-2015. However, after 2015, revenue growth resumed robustly, culminating in a significant jump to over 45 billion USD by 2024, indicating strong sales growth or expansion of the business over the years.
Net profit margin also shows considerable variation that aligns with the fluctuations in net income. Margins started at 13.52% in 2005, saw an improvement reaching over 21% by 2010, and remained relatively stable until the sharp decline in 2008 coinciding with the net loss recorded that year. The margin dipped near zero in 2017 but recovered thereafter, reaching an exceptionally high margin of 37.27% in 2019, suggesting a year of significantly improved profitability. This was followed by a decline and stabilization in the 15% to 25% range in subsequent years. Despite some variability, the overall level of profitability as measured by net margins appears sustainable and relatively high by the end of the period examined.
- Net Income Analysis
- Large fluctuations with intermittent losses, strong recovery periods, and a peak in 2024.
- Revenue Trends
- Consistent growth overall, with temporary slowdowns and a strong upward trend reaching a peak near 45 billion USD.
- Profit Margin Insights
- Margins correlate with net income patterns, with a marked peak in 2019 and recovery after downturns, indicating improved efficiency or profitability drivers during high-margin periods.
Comparison to Competitors
Eli Lilly & Co., net profit margin, long-term trends, comparison to competitors
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 23.51% | 7.59% | 12.77% | -18.53% | 16.33% | 1.68% | 15.84% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| Dec 31, 2023 | 15.36% | 8.95% | 24.96% | 17.83% | 19.94% | 21.03% | 41.28% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| Dec 31, 2022 | 21.88% | 20.39% | 26.42% | 13.71% | 22.91% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 19.71% | 20.54% | 24.25% | 15.08% | 21.84% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | 25.24% | 10.08% | 29.97% | -21.20% | 16.36% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 37.27% | 23.69% | 35.32% | 13.15% | 16.80% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 13.16% | 17.36% | 37.25% | 21.81% | 13.33% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | -0.89% | 18.82% | 9.08% | 4.85% | 13.60% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 12.90% | 23.22% | 35.27% | 22.94% | 15.13% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 12.07% | 22.50% | 33.13% | 9.45% | 16.33% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 12.19% | 8.89% | 26.69% | 12.62% | 13.05% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 20.27% | 21.97% | 27.93% | 15.64% | 14.10% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 18.09% | 28.70% | 26.11% | 11.12% | 13.10% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 17.90% | — | 24.08% | 17.46% | 13.50% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 21.97% | — | 31.56% | 15.92% | 13.58% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 19.82% | — | 32.09% | 56.42% | 10.30% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | -10.17% | — | 28.57% | 25.47% | 10.38% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 15.85% | — | 22.12% | 11.19% | 12.42% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 16.97% | — | 21.29% | 8.85% | 11.69% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 13.52% | — | 30.56% | 15.62% | 11.24% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 23.51% | 12.30% |
| Dec 31, 2023 | 15.36% | 17.95% |
| Dec 31, 2022 | 21.88% | 22.55% |
| Dec 31, 2021 | 19.71% | 23.38% |
| Dec 31, 2020 | 25.24% | 14.07% |
| Dec 31, 2019 | 37.27% | 23.22% |
| Dec 31, 2018 | 13.16% | 19.82% |
| Dec 31, 2017 | -0.89% | 13.06% |
| Dec 31, 2016 | 12.90% | 20.78% |
| Dec 31, 2015 | 12.07% | 21.17% |
| Dec 31, 2014 | 12.19% | 21.24% |
| Dec 31, 2013 | 20.27% | 21.99% |
| Dec 31, 2012 | 18.09% | 18.53% |
| Dec 31, 2011 | 17.90% | 15.70% |
| Dec 31, 2010 | 21.97% | 15.16% |
| Dec 31, 2009 | 19.82% | 25.73% |
| Dec 31, 2008 | -10.17% | 18.17% |
| Dec 31, 2007 | 15.85% | 15.90% |
| Dec 31, 2006 | 16.97% | 22.24% |
| Dec 31, 2005 | 13.52% | 18.33% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Eli Lilly & Co., net profit margin, long-term trends, comparison to industry (health care)
| Eli Lilly & Co. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 23.51% | 7.02% |
| Dec 31, 2023 | 15.36% | 9.24% |
| Dec 31, 2022 | 21.88% | 11.62% |
| Dec 31, 2021 | 19.71% | 12.42% |
| Dec 31, 2020 | 25.24% | 8.45% |
| Dec 31, 2019 | 37.27% | 11.58% |
| Dec 31, 2018 | 13.16% | 9.92% |
| Dec 31, 2017 | -0.89% | 8.05% |
| Dec 31, 2016 | 12.90% | 10.68% |
| Dec 31, 2015 | 12.07% | 11.77% |
| Dec 31, 2014 | 12.19% | 12.15% |
| Dec 31, 2013 | 20.27% | 12.81% |
| Dec 31, 2012 | 18.09% | 11.86% |
| Dec 31, 2011 | 17.90% | 10.50% |
| Dec 31, 2010 | 21.97% | 10.48% |
| Dec 31, 2009 | 19.82% | 15.08% |
| Dec 31, 2008 | -10.17% | 11.35% |
| Dec 31, 2007 | 15.85% | 11.02% |
| Dec 31, 2006 | 16.97% | 13.95% |
| Dec 31, 2005 | 13.52% | 13.38% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).